| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 72485-0216-08 | 72485-0216 | Docetaxel | Docetaxel | 160.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan 15, 2020 | In Use | |
| 00409-0366-01 | 00409-0366 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 24, 2016 | In Use | |
| 16729-0231-64 | 16729-0231 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 30, 2012 | Jun 21, 2019 | In Use |
| 00703-5730-01 | 00703-5730 | Docetaxel | Docetaxel | 80.0 mg/4mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec 31, 2015 | Nov 30, 2018 | No Longer Used |
| 24979-0710-51 | 24979-0710 | Paclitaxel | Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Apr 1, 2022 | May 31, 2025 | No Longer Used |
| 25021-0222-07 | 25021-0222 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 1, 2013 | Mar 31, 2017 | No Longer Used |
| 63323-0763-06 | 63323-0763 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 15, 2014 | Jan 31, 2017 | In Use |
| 51991-0938-98 | 51991-0938 | Paclitaxel | Paclitaxel | 300.0 mg/50mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 22, 2017 | May 31, 2019 | No Longer Used |
| 00703-3213-01 | 00703-3213 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 7, 2020 | In Use | |
| 67457-0434-51 | 67457-0434 | Paclitaxel | Paclitaxel | 300.0 mg/50mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 7, 2014 | Mar 31, 2021 | No Longer Used |
| 67457-0471-52 | 67457-0471 | Paclitaxel | Paclitaxel | 30.0 mg/5mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 7, 2014 | Feb 28, 2021 | No Longer Used |
| 16729-0267-64 | 16729-0267 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 2, 2013 | In Use | |
| 67457-0532-08 | 67457-0532 | DOCETAXEL ANHYDROUS | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sep 28, 2018 | In Use | |
| 70710-2093-04 | 70710-2093 | Docetaxel | BEIZRAY | 20.0 mg/1ml | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 28, 2025 | In Use | |
| 00703-4768-01 | 00703-4768 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sep 16, 2009 | Nov 30, 2019 | In Use |
| 25021-0213-17 | 25021-0213 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sep 27, 2011 | Oct 31, 2016 | No Longer Used |
| 70710-2092-08 | 70710-2092 | Docetaxel | BEIZRAY | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec 15, 2025 | In Use | |
| 67457-0449-17 | 67457-0449 | Paclitaxel | Paclitaxel | 100.0 mg/16.7mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 7, 2014 | Oct 31, 2020 | No Longer Used |
| 00703-3218-01 | 00703-3218 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 5, 2020 | In Use | |
| 25021-0255-05 | 25021-0255 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb 1, 2024 | In Use | |
| 00703-3216-01 | 00703-3216 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 25, 2020 | In Use | |
| 72485-0215-04 | 72485-0215 | Docetaxel | Docetaxel | 80.0 mg/4mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan 15, 2020 | In Use | |
| 00955-1021-04 | 00955-1021 | Docetaxel | Docetaxel | 80.0 mg/4mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 21, 2010 | In Use | |
| 00143-9384-01 | 00143-9384 | FOSAPREPITANT DIMEGLUMINE | FOSAPREPITANT DIMEGLUMINE | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sep 8, 2020 | In Use | |
| 00006-0461-01 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Mar 26, 2003 | In Use |
Found 12250 results — Export these results
Home